Evaluating diastolic dysfunction as an indicator of cirrhotic cardiomyopathy in decompensated chronic liver disease

Abstract

Cirrhosis, a term coined by French physician René Laënnec in 1819, is characterized by histological 
alterations in the regenerating clusters of liver cells, which exhibit nodules and extensive fibrous septae. 
It is a significant contributor to global health burdens that can be prevented but is not fully recognized. 
According to estimates from the World Health Organization (WHO), cirrhosis is responsible for 2.4% of 
global deaths, and this percentage may increase in the future. Cirrhotic cardiomyopathy (CCM) is one of 
the potential outcomes of cirrhosis or decompensated liver disease. It is a myocardial condition 
characterized by impaired cardiac pumping function and often accompanied by arrhythmia. 
Cardiomyopathy, as defined by the American Heart Association, refers to a wide range of abnormalities 
in the heart muscle.